Broad coverage of pharmacology in a prestigious journal

THE JOURNAL OF
PHARMACOLOGY AND
EXPERIMENTAL THERAPEUTICS

Editor: Eva King Killam, PhD, School of Medicine, University of California, Davis

JPET is respected the world over as one of the leading research journals in the field of pharmacology. Readers find broad coverage of all aspects of the interactions of chemicals with biological systems, including:
- autonomic pharmacology
- analgesia
- cardiovascular pharmacology
- cellular pharmacology
- chemotherapy
- clinical pharmacology
- developmental pharmacology
- drug abuse
- drug metabolism & disposition
- gastrointestinal pharmacology
- immunopharmacology
- neuropharmacology
- pulmonary pharmacology
- renal pharmacology
- toxicology

JPET is valuable reading for academic, industrial and clinical pharmacologists as well as toxicologists. The Journal deserves a place in every pharmaceutical and toxicological research laboratory and pharmacology/toxicology department throughout the world.

Monthly

YES! Enter my subscription:

Avoid future rate increases and ensure uninterrupted service - enter your multiyear subscription today!

The Journal of Pharmacology and Experimental Therapeutics
(monthly)
- Individual $160 yr
- Institutions $200 yr
- New Subscription
- Renewal
- 3 yrs
- 2 yrs
- 1 yr

Payment options:
- Check enclosed
- Visa
- MasterCard
- American Express

Card #
signature

MD residents, please add 5% sales tax. Subscriptions from outside the US and Canada must be prepaid, and US dollars only. Rates valid for orders received before December 31, 1990.

Please allow 10 weeks for delivery of your first issue. Surface mail delivery to countries outside the US may take up to 6 weeks. Annual rates available upon request.

Williams & Wilkins
P.O. Box 2839
Baltimore, Maryland 21203-9990

Broadway House
20 Fulham Broadway
London SW6 3JG England

PT 52004

J0020601
STABLE EXPRESSION OF HUMAN DRUG METABOLISM IN CELL CULTURE

GENTEST Corporation announces the development of immortal human lymphoblastoid cell lines which stably express human cytochrome P450s. These cell lines provide a reproducible source of human cytochrome P450s. The cell lines and microsomal preparations from the cell lines are available for toxicology and pharmacology research applications. This system:

- Provides a convenient means to analyze human metabolites.
- Provides an unlimited source of reproducible material.
- Avoids the large variability among human tissue samples.
- Allows analysis of cytochrome P450 form specificity without laborious purifications of enzymes or antibodies.
- Provides a means to analyze for clinically significant drug metabolism polymorphism early in drug development.
- Allows measurement of cytotoxicity and the induction of genetic damage in cells expressing the cytochrome P450.

The following human cytochrome P450s have been stably expressed by GENTEST in cell culture:

<table>
<thead>
<tr>
<th>P450</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>P450IA1</td>
<td>Aryl Hydrocarbon Hydroxylase</td>
</tr>
<tr>
<td>P450IA2</td>
<td>Phenacetin O-Deethylase</td>
</tr>
<tr>
<td>P450IA3</td>
<td>Coumarin Hydroxylase</td>
</tr>
<tr>
<td>P450ID6</td>
<td>Debrisoquine Hydroxylase</td>
</tr>
<tr>
<td>P450IIA4</td>
<td>Nifedipine Oxidase</td>
</tr>
</tbody>
</table>

Cell lines expressing additional human cytochrome P450s are under development.

For further information contact:

GENTEST Corporation
6 Henshaw Street
Woburn, MA 01801 USA
Tel: (617) 935-5115
FAX: (617) 938-8644